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Abstract. Renal cell carcinoma (RCC) is a common urological 
cancer worldwide and is known to have a high risk of metas-
tasis, which is considered responsible for more than 90% 
of cancer associated deaths. Honokiol is a small-molecule 
biphenol isolated from Magnolia spp. bark and has been 
shown to be a potential anticancer agent involved in multiple 
facets of signal transduction. In this study, we demonstrated 
that honokiol inhibited the invasion and colony formation of 
highly metastatic RCC cell line 786-0 in a dose-dependent 
manner. DNA-microarray data showed the significant upregu-
lation of metastasis-suppressor gene KISS1 and its receptor, 
KISS1R. The upregulation was confirmed by qRT-PCR 
analysis. Overexpression of KISS1 and KISS1R was detected 
by western blotting at the translation level as well. Of note, the 
decreased invasive and colonized capacities were reversed by 
KISS1 knockdown. Taken together, the results first indicate that 
activation of KISS1/KISS1R signaling by honokiol suppresses 
multistep process of metastasis, including invasion and colony 
formation, in RCC cells 786-0. Honokiol may be considered as 
a natural agent against RCC metastasis.
Introduction
Metastasis is the tendency of cancer cells to spread to distant 
organs in the body, which is considered responsible for more 
than 90% of cancer-associated deaths (1-4). It involves a multi-
step process including migration from the primary tumors, 
invasion to surrounding tissues, and proliferation leading to 
the colonization at distant sites (1,4). Accordingly, 25-30% 
of patients with renal cell carcinoma (RCC) have metastatic 
spread by the time they are diagnosed (5-7) and in these cases, 
the 5-year survival rate of patients is <10% (8,9). Moreover, 
20-25% of suffers remain unresponsive to all treatments and 
the disease progresses rapidly (10,11). Honokiol, a small-
molecule biphenolic compound isolated from Magnolia spp. 
Bark, has been shown to exhibit anticancer effects in different 
cancer types (12-17). The most widely investigated mecha-
nism of its anticancer activities is apoptosis, which is induced 
in vitro and in vivo through multiple facets of signal transduc-
tion (12,14,16-25). Recently, several studies demonstrated that 
honokiol could also inhibit metastasis of breast, brain, gastric, 
lung and prostate cancer cells (13,21,26-32). However, only one 
study shows the metastasis suppression of RCC cells A-498 by 
honokiol through reversing epithelial-mesenchymal transition 
and blocking cancer stem cell properties (33). Definitely, there 
are other important targets involved in the process of RCC 
metastasis suppression by honokiol.
In this study, we found that honokiol inhibits the inva-
sion and colony formation of highly metastatic RCC cells 
786-0 (34) in a dose-dependent manner. DNA-microarray data 
showed significant upregulation of metastasis-suppressor gene 
KISS1 and its receptor, KISS1R. Both of the upregulation were 
confirmed by qRT-PCR analysis. Overexpression levels of 
KISS1 and KISS1R were detected by western blotting at the 
translation level as well. Of note, inhibition of invasion and 
colony formation were reversed by KISS1 knockdown. Taken 
together, our results indicate that honokiol suppresses the 
multistep process of metastasis, including invasion and colony 
formation, in RCC cells 786-0 via stimulation of KISS1/
KISS1R signaling pathway.
Materials and methods
Cell culture and reagents. Human RCC cells 786-0 were 
obtained from ATCC (Manassas, VA, USA). Cancer cells were 
maintained according to the ATCC procedures. Honokiol 
(98%) (HonoPure®) was provided by Econugenics Inc. (Santa 
Rosa, CA, USA) and dissolved in DMSO at a concentration 
of 80 mM then stored at -20˚C. DMSO was purchased from 
Sigma (St. Louis, MO, USA). Anti-KISS1, anti-KISS1R 
and anti-β-actin antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).
Cell invasion assay. Cell invasion of 786-0 cells treated with 
honokiol (0-20 µM) was performed as previously described (35). 
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Data points represent the mean ± SD of three individual filters 
within one representative experiment repeated at least twice.
Colony formation assay. Colony formation of the 786-0 cells 
incubated in the presence of honokiol (0-40 µM) was evaluated as 
previously described (36). Data points represent the mean ± SD 
in one representative experiment repeated at least twice.
DNA-microarray and quantitative RT-PCR analysis. The 
786-0 cells were treated with honokiol (0, 40 µM) for 24 h and 
TaqMan® Array Human Tumor metastasis was performed as 
previously described (37). In qRT-PCR analysis, the 786-0 cells 
were treated with honokiol (0-40 µM) for 24 h. Isolation, 
quantification, reverse transcription of RNA and PCR were 
performed as previously described (37). Relative quantity (RQ) 
of gene expression was normalized to β-actin and performed 
using the 2-∆∆Ct method (38).
Western blot analysis. The 786-0 cells were treated with 
honokiol (0-40 µM) for 24 h. Whole protein extracts isolated 
from cells were prepared and western blot analysis with 
KISS1 and KISS1R antibodies were performed as previously 
described (39). Western blots were quantified with HP-Scanjet 
550c and analyzed by UN-SCAN-IT software (Silk Scientific, 
Orem, UT, USA).
siRNA transfection. The 786-0 cells were transfected with human 
KISS1 siRNA or control siRNA-A as previously described (37). 
After 48 h of transfection, the cells were harvested and KISS1 
knockdown was verified by western blot analysis.
Statistical analysis. All the statistical analysis was performed 
using SigmaPlot 11.2.0 (Systat Software Inc., San Jose, CA, 
USA). Data are presented as mean ± SD. Statistical compari-
sons were carried out using ANOVA with the significance level 
adjusted using the repeated t-tests with Bonferroni correction. 
P-value <0.05 was considered to be significant.
Results
Honokiol inhibits invasion and colony formation of highly 
metastatic RCC cells. To evaluate whether honokiol (Fig. 1) 
suppresses invasive behavior of highly metastatic RCC cells, 
the 786-0 cells were treated with honokiol (0-20 µM) for 24 h 
and cell invasion was determined as described in Materials 
and methods. As shown in Fig. 2A, honokiol inhibits cell inva-
sion through Matrigel in a dose-dependent manner. Moreover, 
honokiol significantly decreases the number of anchorage-
independent colonies formed, which is a key step in cancer 
metastasis (Fig. 2B and C). In summary, honokiol significantly 
inhibits invasion as well as colony formation of highly meta-
static RCC 786-0 cells in a dose-dependent manner.
Effect of honokiol on the expression of genes related to human 
tumor metastasis. In order to gain further mechanistic insight 
into the molecular events underlying metastasis inhibition 
of the 786-0 cells treated with honokiol, DNA-microarray 
analysis of 92 tumor metastasis-associated genes and 4 
candidate endogenous control genes was performed. Table I 
summarizes the genes with large recurring expression 
differences compared with control. For example, significant 
upregulation was observed including the expression of metas-
tasis suppressor gene (KISS-1, 28.56±11.17), genes encoding 
TIMP metalloproteinase inhibitor 4 (TIMP4, 14.25±4.04) 
and KISS-1 receptor (KISS-1R, 13.33±5.11). In addition, 
honokiol markedly suppresses expression of genes encoding 
chemokine (C-X-C motif) ligand 12 (CXCL12, 0.13±0.05), 
chemokine (C-C motif) ligand 7 (CCL7, 0.14±0.04), inter-
leukin-18 (IL18, 0.23±0.05) and matrix metallo proteinase 7 
(MMP7, 0.26±0.09).
Honokiol activates KISS1/KISS1R signaling in highly meta-
static RCC cells. Since recent studies showed that activation 
of KISS1/KISS1R signaling by kisspeptin treatment decreases 
the motility and invasive capacity of conventional RCC, 
and overexpression of KISS1 inhibits invasion of RCC cells 
Caki-1 (40,41), we confirmed the significant upregulation of 
KISS1 and KISS1R in the 786-0 cells treated with honokiol by 
qRT-PCR (Fig. 3). In accordance with the change in mRNA, 
western blot analysis showed that honokiol stimulates expres-
sion of KISS1 and KISS1R in the 786-0 cells dose-dependently 
at the protein level (Fig. 4).
Figure 1. Structure of honokiol.
Table I.  Effect of honokiol on the expression of human tumor 
metastasis genes.
Gene  Description  RQ
KISS1 KISS-1 metastasis suppressor  28.56±11.17a
TIMP4 TIMP metalloproteinase inhibitor 4  14.25±4.04a
KISS1R KISS1 receptor 13.33±5.11a
TP53 P53 tumor suppressor 2.24±0.16
CXCL12 Chemokine (C-X-C motif) ligand 12 0.13±0.05
CCL7 Chemokine (C-C motif) ligand 7 0.14±0.04
IL18 Interleukin-18 0.23±0.05
MMP7 Matrix metalloproteinase 7 0.26±0.09
VEGFC Vascular endothelial growth factor C  0.42±0.04
FGFR4 Fibroblast growth factor receptor 4 0.53±0.04
DNA-microarray analysis was performed on TaqMan® Array Human 
Tumor Metastasis as described in Materials and methods. The 
786-0 cells were treated with honokiol (0 and 40 µM) for 24 h. Data 
are the means ± SD of three independent experiments. Analysis of the 
relative quantity gene expression (RQ) data was performed using the 
2-∆∆CT method. Statistical analysis by ANOVA, aP<0.05.
INTERNATIONAL JOURNAL OF ONCOLOGY  46:  2293-2298,  2015 2295
Silencing KISS1 reverses suppression of invasion and colony 
formation. To determine whether the suppression of invasion 
and colony formation by honokiol are associated with the 
activation of KISS1/KISS1R signaling in the 786-0 cells, we 
silenced KISS1 with siRNA as described in Materials and 
methods. As shown in Fig. 5, knockdown of KISS1 partially 
rescues the effect of honokiol on cell invasion by more than 
40%. Moreover, the effect of honokiol on colony formation 
of the 786-0 cells is markedly reversed by KISS1 silencing 
(Fig. 6). These results further indicate that KISS1/KISS1R 
signaling is a major target of honokiol in suppressing metas-
tasis of RCC cells.
Discussion
In the present study, we investigated the role of honokiol in 
the metastasis of RCC cells. Our results showed that honokiol 
significantly inhibited the invasion and colony formation 
of highly metastatic RCC cells 786-0 in a dose-dependent 
manner. Moreover, honokiol markedly upregulated metas-
tasis-suppressor gene KISS1 and its receptor, KISS1R, at both 
transcription and translation levels. Interestingly, knockdown 
of KISS1 partially rescued the effect of honokiol on cell 
invasion and its effect on colony formation of the 786-0 cells 
is reversed as well, indicating that KISS1/KISS1R signaling 
Figure 2. Effect of honokiol on the invasion and colony formation of the 786-0 cells. The 786-0 cells were treated with honokiol (A) (0-20 µM) or (B) (0-40 µM). 
Cell invasion through Matrigel and colony formation in agarose were determined as described in Materials and methods. Each bar represents the mean ± SD 
in one representative experiment repeated at least twice. Representative pictures of colony formation are shown (C). Statistical analysis by ANOVA, *P<0.05.
Figure 3. Honokiol stimulates mRNA expression of KISS1 and KISS1R in the 786-0 cells. The 786-0 cells were treated with honokiol (0-40 µM) for 24 h and 
qRT-PCR analysis on KISS1 and KISS1R were performed as described in Materials and methods. Each bar represents the mean ± SD of three independent 
experiments. Statistical analysis by ANOVA, *P<0.05.
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is a major target of honokiol in suppressing metastasis of 
RCC cells.
Metastasis suppressors are defined as molecules whose 
expression results in the suppression of metastasis processes 
and since 1986, more than 13 metastasis suppressors have been 
identified (42). The KISS1 gene, initially discovered as a novel 
human malignant melanoma metastasis-suppressor gene (43), 
has been validated as an anti-metastatic gene by preclinical and 
clinical evidence in various types of cancer (44). The encoded 
KISS1 protein can be processed to a C-terminally amidated 
peptide termed metastin binding and activating the G-protein 
coupled receptor GPR54 (KISS1R) (45). Shoji et al found 
that metastin inhibited migration and invasion of RCC with 
overexpression of KISS1R (46). In addition, a recent study 
demonstrated that an absence of KISS1R expression was asso-
ciated with rapid progression of conventional RCC in patients 
(40), suggesting KISS1/KISS1R signaling as a promising 
target in RCC.
Figure 4. Honokiol induces expression of KISS1 and KISS1R in the 786-0 cells. The 786-0 cells were treated with honokiol (0-40 µM) for 24 h and the 
expression of KISS1 and KISS1R were evaluated by western blot analysis as described in Materials and methods. Representative results are shown. Similar 
results were obtained in at least two additional experiments.
Figure 5. KISS1 gene silencing partially rescues the effect of honokiol on cell invasion. The 786-0 cells were transfected with scrambled siRNA (siRNA-A) 
or KISS1 siRNA as described in Materials and methods. (A) Western blot analysis of KISS1 was evaluated. (B) Invasion of the 786-0 cells through Matrigel 
was determined as described in Fig. 2A. Each bar represents the mean ± SD of three individual filters within one representative experiment repeated at least 
twice. Statistical analysis by ANOVA, *P<0.05.
Figure 6. KISS1 gene silencing reverses the effect of honokiol on colony formation. The 786-0 cells were transfected with scrambled siRNA (siRNA-A) or KISS1 
siRNA as described in Materials and methods. (A) Colony formation of the 786-0 cells in agarose was determined as described in Fig. 2B. (B) Representative 
images of colony formation are shown. Each bar represents the mean ± SD in one representative experiment repeated at least twice. Statistical analysis by 
ANOVA, *P<0.05.
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Honokiol targets multiple signaling pathways such as 
nuclear factor κB (NF-κB), signal transducers and activator 
of transcription 3 (STAT3), mammalian target of rapamycin 
(mTOR) and epidermal growth factor receptor (EGFR), which 
have great relevance during cancer initiation and progres-
sion (47). Moreover, pharmacokinetic studies revealed that 
honokiol crossed the blood-brain barrier (BBB), the blood-
cerebrospinal fluid barrier (BCSFB) and had a desirable 
bioavailability after intravenous administration in animal 
models (48) thus making it a suitable agent for clinical trials.
In summary, our results indicate that activation of KISS1/
KISS1R signaling by honokiol decreases the invasiveness 
and colonized capacity of highly metastatic RCC cells. 
Furthermore, we confirmed that honokiol stimulated the 
expression of TIMP4 dose-dependently (data not shown). It 
is in accordance with the finding that metastin suppresses 
the motility and invasive ability of RCC cells which possess 
KISS1R through the downregulation of MMP-2 (49). As 
emerging studies show that KISS1R activates a series of 
signaling molecules such as protein kinase C (PKC), extra-
cellular signal-regulated kinases 1 and 2 (ERK1/2), p38, and 
phosphatidylinositol-3-kinase (PI3K) (50), further studies are 
in progress to investigate the specific mechanism of honokiol, 
which may have the potential for use as a natural agent against 
RCC metastasis.
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